The FDA unveiled a new pilot program that aims to speed up review times for generic drugmakers who test and manufacture their products in the U.S. Separately, the agency met with industry stakeholders this week to take comments on a
read morePatients and providers often enter the exam room misaligned. A 360° data strategy may be pharma’s missing link. More: Bridging the patient-provider gap with 360° data Source: fierce
read moreIn a letter inked to the U.K.’s Competition and Markets Authority, three advocacy organizations called the recent string of Big Pharma companies pulling their U.K. investments a coordinated scheme for “anti-competitive purposes.” More: Big Pharma's 'Brexit' draws call for anticompetition
read moreBiopharma is set to lose two of the industry’s rare women CEOs—GSK’s Emma Walmsley and Merck KGaA’s Belén Garijo—leaving a dearth of women-helmed large life sciences companies. More: 4 reasons why life sciences still fail women at the top, despite
read moreThe FDA has approved Jazz Pharmaceuticals’ Zepzelca, used in combination with Roche’s Tecentriq, as a first-line maintenance treatment in extensive-stage small cell lung cancer More: With FDA approval, Jazz and Roche's combo sets new bar in first-line small cell lung
read moreVaxcyte is paying Thermo Fisher Scientific up to $1 billion to access vaccine fill-finish capacity at the CDMO’s production facility in Greenville, North Carolina. Vaxcyte positioned the deal as a “long-term U.S. commercial manufacturing commitment.” More: Vaxcyte strikes up to
read more© 1994 - 2026 B.M. Pharmaceuticals